PRKAA2 and cardiac hypertrophy: These findings not only elucidate the molecular mechanisms underlying PF's cardioprotective effects but also highlight the potential of targeting the AMPK–HSP70 axis as a treatment for pathological cardiac hypertrophy and HF.